NO20083968L - Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdom - Google Patents
Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdomInfo
- Publication number
- NO20083968L NO20083968L NO20083968A NO20083968A NO20083968L NO 20083968 L NO20083968 L NO 20083968L NO 20083968 A NO20083968 A NO 20083968A NO 20083968 A NO20083968 A NO 20083968A NO 20083968 L NO20083968 L NO 20083968L
- Authority
- NO
- Norway
- Prior art keywords
- prevent
- receptor antagonists
- adenosine receptor
- hepatic disease
- treat hepatic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Oppfinnelsen angår fremgangsmåter for å forebygge og behandle leversykdom ved bruk av A2B-reseptorantagonister og anvendelse av behandlingen for å forhindre leverskade forårsaket av alkoholmisbruk, kirurgisk inngrep, viral hepatitt, inntak av hepatotoksiske droger eller andre leversykdommer. Oppfinnelsen angår også farmasøytiske preparater for anvendelse ved denne fremgangsmåte.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78357506P | 2006-03-17 | 2006-03-17 | |
PCT/US2007/064182 WO2007109547A2 (en) | 2006-03-17 | 2007-03-16 | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20083968L true NO20083968L (no) | 2008-12-15 |
Family
ID=38514256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20083968A NO20083968L (no) | 2006-03-17 | 2008-09-17 | Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdom |
Country Status (14)
Country | Link |
---|---|
US (4) | US7795268B2 (no) |
EP (1) | EP1996201A2 (no) |
JP (2) | JP5250848B2 (no) |
KR (1) | KR101428113B1 (no) |
CN (1) | CN101405003B (no) |
AU (1) | AU2007227021B2 (no) |
CA (2) | CA2646333C (no) |
IL (1) | IL194158A0 (no) |
MX (1) | MX2008011828A (no) |
NO (1) | NO20083968L (no) |
NZ (1) | NZ571324A (no) |
RU (1) | RU2457842C2 (no) |
WO (1) | WO2007109547A2 (no) |
ZA (1) | ZA200807894B (no) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7317017B2 (en) | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US20080194593A1 (en) * | 2001-11-09 | 2008-08-14 | Rao Kalla | A2b adenosine receptor antagonists |
US20080318983A1 (en) * | 2001-11-09 | 2008-12-25 | Rao Kalla | A2b adenosine receptor antagonists |
CA2536553C (en) * | 2003-08-25 | 2013-01-29 | Adenosine Therapeutics, Llc | Substituted 8-heteroaryl xanthines |
RU2391103C2 (ru) | 2004-10-15 | 2010-06-10 | Си Ви Терапьютикс, Инк. | Способ предупреждения и лечения ремоделирования дыхательных путей и воспаления легких с применением антагонистов аденозиновых рецепторов a2b |
WO2006091898A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyrazolyl substituted xanthines |
WO2006091897A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Derivatives of 8-substituted xanthines |
WO2006091936A2 (en) | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
AU2006259411B2 (en) * | 2005-06-16 | 2012-03-22 | Gilead Sciences, Inc. | Prodrugs of A2B adenosine receptor antagonists |
JP5250848B2 (ja) | 2006-03-17 | 2013-07-31 | ギリアード サイエンシーズ, インコーポレイテッド | A2bアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法 |
US7884100B2 (en) * | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
US7906518B2 (en) * | 2006-06-27 | 2011-03-15 | Cbt Development Limited | Therapeutic compounds |
US7767685B2 (en) * | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
WO2009055021A1 (en) * | 2007-10-26 | 2009-04-30 | New York University School Of Medicine | Methods and compositions for treating hepatic diseases |
US7875608B2 (en) * | 2007-12-17 | 2011-01-25 | Thompson Robert D | Substituted 8-[6-amino-3pyridyl]xanthines |
WO2009118759A2 (en) | 2008-03-26 | 2009-10-01 | Advinus Therapeutics Pvt. Ltd., | Heterocyclic compounds as adenosine receptor antagonist |
BRPI1009398A2 (pt) | 2009-03-13 | 2016-03-08 | Advinus Therapeutics Private Ltd | compostos de pirimidina fundida substituída |
JP5843778B2 (ja) | 2009-11-09 | 2016-01-13 | アドヴィナス・セラピューティックス・リミテッド | 置換縮合ピリミジン化合物、その調製およびその使用 |
JP5827998B2 (ja) | 2010-09-13 | 2015-12-02 | アドヴィナス・セラピューティックス・リミテッド | A2bアデノシン受容体アンタゴニストのプロドラッグとしてのプリン化合物、これらの方法および薬剤の適用 |
US20140142113A1 (en) * | 2012-11-09 | 2014-05-22 | Michael W. Burnet | Method of treating inflammatory diseases using adenosine 2b receptor antagonists |
WO2016057454A1 (en) | 2014-10-06 | 2016-04-14 | The Johns Hopkins University | Targeting liver nuclear receptors as a treatment for wilson disease |
WO2016129760A1 (ko) * | 2015-02-13 | 2016-08-18 | 한국과학기술원 | Tnp(n2-(m-trifluorobenzyl), n6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물 |
KR101666605B1 (ko) | 2015-02-13 | 2016-10-18 | 한국과학기술원 | TNP(N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물 |
JP6761857B2 (ja) | 2015-10-29 | 2020-09-30 | シーエルエス セラピューティクス リミテッドCLS Therapeutics Limited | 抗癌療法の安全性および有効性を改善する方法 |
AU2017217688B2 (en) | 2016-02-10 | 2023-01-19 | Wake Forest University Health Sciences | Model system of liver fibrosis and method of making and using the same |
KR101709307B1 (ko) | 2016-10-31 | 2017-02-23 | 퓨쳐메디신 주식회사 | 아데노신 유도체를 포함하는 비알콜성 지방간염, 간섬유증 및 간경변증 예방 및 치료용 약학적 조성물 |
JP7189155B2 (ja) * | 2017-05-17 | 2022-12-13 | アーカス バイオサイエンシズ インコーポレイティド | 癌関連障害の治療のためのキナゾリン-ピラゾール誘導体 |
KR20200061346A (ko) * | 2017-08-31 | 2020-06-02 | 코버스 파마슈티칼스, 인크. | 아데노신 a2b 수용체 및 아데노신 a2a 수용체를 조절하기 위한 화합물 및 방법 |
WO2019173380A1 (en) | 2018-03-05 | 2019-09-12 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
CN112996509B (zh) | 2018-07-27 | 2024-10-01 | 艾库斯生物科学有限公司 | 吡啶酮a2r拮抗剂 |
CN111686239B (zh) * | 2019-03-11 | 2021-12-24 | 中国科学院微生物研究所 | 抗真菌化合物的应用 |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0028383D0 (en) * | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
US7125993B2 (en) * | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
RU2318824C2 (ru) * | 2001-11-09 | 2008-03-10 | Си Ви Терапьютикс, Инк. | Антагонисты рецептора аденозина a2b, фармацевтическая композиция на их основе и способ их получения |
ES2208063B1 (es) * | 2002-04-01 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida. |
EP1549319A2 (en) * | 2002-05-30 | 2005-07-06 | King Pharmaceuticals Research and Development Inc. | Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use |
WO2004086052A2 (en) | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a2b (adora2b) |
GB0401336D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
AU2006259411B2 (en) * | 2005-06-16 | 2012-03-22 | Gilead Sciences, Inc. | Prodrugs of A2B adenosine receptor antagonists |
JP5250848B2 (ja) * | 2006-03-17 | 2013-07-31 | ギリアード サイエンシーズ, インコーポレイテッド | A2bアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法 |
-
2007
- 2007-03-16 JP JP2009501667A patent/JP5250848B2/ja active Active
- 2007-03-16 CN CN2007800095071A patent/CN101405003B/zh active Active
- 2007-03-16 US US11/687,236 patent/US7795268B2/en active Active
- 2007-03-16 KR KR1020087022707A patent/KR101428113B1/ko active IP Right Grant
- 2007-03-16 MX MX2008011828A patent/MX2008011828A/es active IP Right Grant
- 2007-03-16 RU RU2008137279/15A patent/RU2457842C2/ru active
- 2007-03-16 NZ NZ571324A patent/NZ571324A/en unknown
- 2007-03-16 EP EP07758704A patent/EP1996201A2/en not_active Withdrawn
- 2007-03-16 CA CA2646333A patent/CA2646333C/en active Active
- 2007-03-16 AU AU2007227021A patent/AU2007227021B2/en active Active
- 2007-03-16 WO PCT/US2007/064182 patent/WO2007109547A2/en active Application Filing
- 2007-03-16 CA CA2849661A patent/CA2849661A1/en not_active Abandoned
-
2008
- 2008-09-15 ZA ZA200807894A patent/ZA200807894B/xx unknown
- 2008-09-17 IL IL194158A patent/IL194158A0/en unknown
- 2008-09-17 NO NO20083968A patent/NO20083968L/no not_active Application Discontinuation
-
2010
- 2010-08-10 US US12/853,510 patent/US8188099B2/en active Active
-
2012
- 2012-02-28 US US13/407,616 patent/US8609671B2/en active Active
- 2012-12-07 JP JP2012268193A patent/JP2013049719A/ja active Pending
-
2013
- 2013-10-04 US US14/046,847 patent/US20140243358A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20070219221A1 (en) | 2007-09-20 |
KR101428113B1 (ko) | 2014-08-07 |
MX2008011828A (es) | 2008-09-29 |
US20110184002A1 (en) | 2011-07-28 |
AU2007227021A1 (en) | 2007-09-27 |
US8609671B2 (en) | 2013-12-17 |
US7795268B2 (en) | 2010-09-14 |
US20140243358A1 (en) | 2014-08-28 |
JP2013049719A (ja) | 2013-03-14 |
RU2008137279A (ru) | 2010-03-27 |
JP5250848B2 (ja) | 2013-07-31 |
CA2646333A1 (en) | 2007-09-27 |
ZA200807894B (en) | 2009-05-27 |
KR20080107416A (ko) | 2008-12-10 |
US20120220608A1 (en) | 2012-08-30 |
NZ571324A (en) | 2011-07-29 |
WO2007109547A2 (en) | 2007-09-27 |
EP1996201A2 (en) | 2008-12-03 |
CN101405003B (zh) | 2011-05-11 |
CN101405003A (zh) | 2009-04-08 |
JP2009530413A (ja) | 2009-08-27 |
US8188099B2 (en) | 2012-05-29 |
CA2646333C (en) | 2014-06-17 |
AU2007227021B2 (en) | 2012-12-20 |
WO2007109547A3 (en) | 2007-11-29 |
CA2849661A1 (en) | 2007-09-27 |
IL194158A0 (en) | 2009-08-03 |
RU2457842C2 (ru) | 2012-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20083968L (no) | Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdom | |
Qaddir et al. | Computer-aided analysis of phytochemicals as potential dengue virus inhibitors based on molecular docking, ADMET and DFT studies | |
NO20072733L (no) | Doseformer | |
WO2010034670A3 (en) | Host cell kinases as targets for antiviral therapies against hcv infection | |
BRPI0622054B8 (pt) | composto e composição farmacêutica | |
NO20090469L (no) | Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav | |
NO20084747L (no) | Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser | |
EA200900297A1 (ru) | Ингибиторы вируса гепатита с | |
MY169275A (en) | Method of immunization against the four serotypes of dengue | |
NO20064976L (no) | Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser | |
WO2010081082A3 (en) | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | |
WO2014089296A3 (en) | Functionalized benzamide derivatives as antiviral agents against hbv infection | |
BR112012024661A2 (pt) | composto, composição farmacêutica e método de tratamento de um hospedeiro infectado com vírus de hepatite c | |
EA201490654A1 (ru) | Новые ингибиторы вирусной репликации | |
EA201300121A1 (ru) | Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения | |
BR112014016163A8 (pt) | piridoftalazinonas tetra ou penta-cíclicas fundidas como inibidores de parp | |
MX2020005345A (es) | Un método para inhibir o reducir una infección viral por coronavirus. | |
WO2008076392A3 (en) | Compounds useful as protein kinase inhibitors | |
MY145349A (en) | Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor | |
NO20084411L (no) | Tetrahydro-pyrimidoazepiner som modulatorer av TRPVI | |
DK2012764T3 (da) | Farmaceutisk kombination omfattende 3-(3-dimethylamino-1-ethyl-2methyl-propyl)-phenol og paracetamol | |
BRPI0922789A2 (pt) | peptídeo de ligação de albumina intermediador para reconhecimento de doença | |
PA8744101A1 (es) | Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia | |
WO2007092469A3 (en) | Combination of organic compounds | |
ATE528309T1 (de) | Als proteinkinaseinhibitoren geeignete verbindungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |